An investigational prostate cancer tablet zibotentan from AstraZeneca has not succeeded in proving its mettle in a late-stage clinical experiment, hindering the Company's oncology duct.The pill did not enhance survival rates in the study. Therefore, AstraZeneca has not filed the drug for regulator’s approval, at this point of time.
On Monday, a Spokesman said that the Company is working with the examiners over the reasons behind the failure, who are engaged in other studies of the drug.
Zibotentan’s unsuccessfulness to boost survival rates in the Phase III study is not the first for AstraZeneca. Prior this year, Company’s recentin for colon cancer failed to show its worth.
Similarly, in 2009, vandetanib for lung cancer was unsuccessful in showing overall improvement. However, Vandetanib seems to benefit a potentially minor market - thyroid cancer.
Zibotentan, which is supposed to be taken once in a day, is being examined in over 3,000 men who are suffering from prostate cancer.
It is said that two other studies investigating the drug in diverse locales are in progress. One of the studies has hired patients and it is anticipated that it will declare the findings in the latter half of the year 2011.
Meanwhile, AstraZeneca’s Spokesman said, "We remain committed to the future discovery of oncology products".
Via : topnews.us
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.